Background: Topical corticosteroid (TCS) phobia is a fear of steroids, most prevalent among the general steroid users, the origin of anxiety and fear about steroids is still unclear. Although multiple studies have been using the validated TOPICOP© scale to assess the scores of steroid phobia in various skin disorders.
Objectives: The aim of the study was to analyze the steroid phobia among users of topical corticosteroids and also to assess the association between demographical characteristics and TCS phobia.
Methods: A cross-sectional survey was conducted to evaluate the belief and perspectives of TCS in a large range of patients of both genders of all ages. Patients presenting in dermatology clinic with any dermatological complaint, who were being treated or currently on topical steroids were included. TOPICOP© scale was used to assess the topical steroid phobia.
Results: A total of 221 topical steroid users were selected for this study, among them 56 (26.7%) were male and 162 (73.3%) were female. The median of global TOPICOP score was 18% and CI 22-12%, S.D: 6.23. The median score of knowledge and beliefs was 7%, (IQR: 9-4%), S.D: 3.33, while fear showed median 5% (IQR: 7-3%), S.D: 2.24, and 6% (IQR: 8-4%), S.D:2.4 for behavior 96 (43.4%). Patients who were not well aware of steroids but still afraid of using steroids. 112 (50.7%) acknowledged the non-adherence to treatment.
Conclusion: Steroid phobia is more prevalent among uneducated users of topical steroids than among those who are knowledgeable and literate. Healthcare practitioners should counsel their patients about steroids use and related concerns, rather than addressing the issue that is causing fear in patients.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1080/09546634.2021.1959505 | DOI Listing |
Clin Cosmet Investig Dermatol
November 2024
Department of Dermatology, Peking University People's Hospital, Beijing, People's Republic of China.
Objective: Topical corticosteroids (TCS), topical calcineurin inhibitors (TCI), and phosphodiesterase 4 (PDE-4) inhibitors are three common topical anti-inflammatory agents for treating atopic dermatitis (AD). The purpose of our study was to understand Chinese dermatologists' perceptions and the factors influencing their choices of the three agents.
Methods: An online questionnaire survey was conducted between 25 July 2022 and 25 August 2022 among Chinese dermatologists.
J Affect Disord
January 2025
Department of Pathology, School of Basic Medicine, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China. Electronic address:
Malays Fam Physician
August 2024
MBBChBAO, MMed (Int. Med.), AdvMDerm, Department of Medicine, Faculty of Medicine, University Kebangsaan Malaysia, Cheras, Kuala Lumpur, Malaysia. Email:
Introduction: Skin barrier dysfunction is an important component of atopic dermatitis (AD) pathophysiology. Topical corticosteroids (TCSs) are the mainstay therapy, but steroid phobia is emerging due to potential side effects. We aimed to determine the short-term effect of clobetasone butyrate on patients with AD.
View Article and Find Full Text PDFJMIR Form Res
August 2024
Department of Dermatology, American University of Beirut Medical Center, Beirut, Lebanon.
Background: Social media platforms like TikTok are a very popular source of information, especially for skin diseases. Topical steroid withdrawal (TSW) is a condition that is yet to be fully defined and understood. This did not stop the hashtag #topicalsteroidwithdrawal from amassing more than 600 million views on TikTok.
View Article and Find Full Text PDFBr J Dermatol
July 2024
Department of Dermatology, APHM, Marseille, France.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!